← Back to home

EGFR-tki-resistant non-small cell lung cancer with leptomeningeal metastasis

Clinical trials for EGFR-tki-resistant non-small cell lung cancer with leptomeningeal metastasis explained in plain language.

Never miss a new study

Get alerted when new EGFR-tki-resistant non-small cell lung cancer with leptomeningeal metastasis trials appear

Sign up with your email to follow new studies for EGFR-tki-resistant non-small cell lung cancer with leptomeningeal metastasis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Spinal-Fluid injection targets Hard-to-Reach lung cancer spread

Disease control Not yet recruiting

This phase 1 trial tests an experimental drug, sacituzumab tirumotecan (SKB264), given directly into the spinal fluid of people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study enrolls adults who…

Matched conditions: EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER WITH LEPTOMENINGEAL METASTASIS

Phase 1 • Sponsor: Henan Cancer Hospital • Aim: Disease control

Last updated Jul 16, 2026 00:00 UTC

EGFR-tki-resistant non-small cell lung cancer with leptomeningeal metastasis

Get alerted when new EGFR-tki-resistant non-small cell lung cancer with leptomeningeal metastasis trials appear

Spinal-Fluid injection targets Hard-to-Reach lung cancer spread